Guidant files suit against J&J to complete merger

Share this article:
Guidant filed a federal lawsuit yesterday to force Johnson & Johnson to complete its $25.4 billion acquisition of the company, The New York Times reports.
J&J contends the deal is now void because of Guidant's financial and legal problems.
Guidant, based in Indianapolis, disclosed yesterday that the Securities and Exchange Commission has opened a formal investigation into the timing of company disclosures about problem heart devices and trading in company stock. The company is already under investigation by the FDA and the Justice Department in connection with its handling of product safety issues.
The merger agreement, unless salvaged, would be one of the biggest ever to collapse because an acquiring company maintained that its target's value had fallen materially before the deal closed, the assertion J&J has made and Guidant has rejected, The Times reported.
In a statement, J&J said it planned on fighting Guidant's lawsuit, filed in U.S. District Court in Manhattan.
J&J has taken the position that Guidant's problems have affected its long-term outlook. Guidant has described any affect as short term.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...